Daniel Getts, Myeloid Therapeutics CEO
May 18, 2023 07:00 AM EDT
Financing

Ex­clu­sive: Myeloid Ther­a­peu­tics rais­es $73M, bring­ing in ARCH ahead of in vi­vo pro­gram en­ter­ing the clin­ic

Andrew Dunn

Senior Biopharma Correspondent

Myeloid Ther­a­peu­tics has raised a $73 mil­lion Se­ries A2 round that brings ARCH Ven­ture Part­ners in as a new in­vestor, as the biotech pre­pares to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times